Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients trea...
Guardado en:
Autores principales: | Mercedes Lopez-Santalla, Marina Inmaculada Garin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/294509dff2494d93b2dbd15636a9b0cb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MSC therapy for inflammatory bowel disease
por: Mikhail A. Konoplyannikov, et al.
Publicado: (2021) -
CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: E. V. Batorov, et al.
Publicado: (2012) -
Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature
por: Turse EP, et al.
Publicado: (2018) -
Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
por: Igor G. Bakulin, et al.
Publicado: (2021) -
Seminars in inflammatory bowel disease
Publicado: (2001)